{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:42:18Z","timestamp":1792208538453,"version":"4.4.0"},"reference-count":134,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:p>Drug safety in pediatric patients has always been a concern. Major tragedies with drugs in pediatric patients created an environment of caution, but the experience with pediatric legislation and drug development over the past 20\u2009years has eased the cautionary approach to pediatric drug safety. The advent of new methods of safety testing, driven by the movement away from animal use in research, provides new opportunities to screen for and prevent adverse developmental effects of drugs on pediatric patients. One approach that can be explored for use in pediatric developmental safety testing is secondary pharmacology, or screening for off\u2010target drug effects. Secondary pharmacology, which is an established screening mechanism described in ICH S7A, could provide the opportunity to answer important off\u2010target questions. Examples of 12 specific secondary pharmacology targets related to adverse effects on pediatric development are provided. Clinical pharmacology plays a critical role in the interpretation of secondary pharmacology through quantitative studies necessary to validate positive findings and through the final assessment of the risk:benefit associated with these findings. In conclusion, secondary pharmacology screening has the potential to reduce animal testing while addressing two critical objectives: screening drugs for off\u2010target effects and providing information on off\u2010target effects relevant to pediatric developmental safety.<\/jats:p>","DOI":"10.1002\/cpt.70465","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:24:08Z","timestamp":1788495848000},"page":"1227-1239","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Secondary Pharmacology Targets for Pediatric Developmental Safety Assessment of New Drugs: Clinical Pharmacology Considerations"],"prefix":"10.1002","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2005-9301","authenticated-orcid":false,"given":"Gilbert J.","family":"Burckart","sequence":"first","affiliation":[{"name":"Office of Clinical Pharmacology, Center for Drug Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1569-6157","authenticated-orcid":false,"given":"Sherbet","family":"Samuels","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology, Center for Drug Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-2029","authenticated-orcid":false,"given":"Susan M.","family":"Abdel\u2010Rahman","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology, Center for Drug Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-6378","authenticated-orcid":false,"given":"Gelareh","family":"Abulwerdi","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology, Center for Drug Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0345-4230","authenticated-orcid":false,"given":"Elimika","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology, Center for Drug Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-4876","authenticated-orcid":false,"given":"Mohamed A.","family":"Mohamoud","sequence":"additional","affiliation":[{"name":"Office of Pediatric Therapeutics, Office of the Commissioner US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6036-7651","authenticated-orcid":false,"given":"Apoorva","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Department of Computational Biomedicine Cedars\u2010Sinai Medical Center  West Hollywood California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2700-2597","authenticated-orcid":false,"given":"Nicholas","family":"Tatonetti","sequence":"additional","affiliation":[{"name":"Department of Computational Biomedicine Cedars\u2010Sinai Medical Center  West Hollywood California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5487-5692","authenticated-orcid":false,"given":"Rebecca","family":"Racz","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology, Center for Drug Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-25.7.565"},{"key":"e_1_2_11_2_1","unstructured":"US Food and Drug Administration.Roadmap to Reducning Animal Testing in Preclinical Safety Studies<https:\/\/www.fda.gov\/media\/186092\/download?attachment>."},{"key":"e_1_2_11_3_1","unstructured":"National Library of Medicine: Mrs. Winslow's Soothing Syrup for children teething<https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid\u2010101402395\u2010img>."},{"key":"e_1_2_11_4_1","unstructured":"The Caledonian Mercury.Dalby's Carminative ad (1835)(1835) <https:\/\/www.newspapers.com\/>."},{"key":"e_1_2_11_5_1","unstructured":"National Museum of American History.Godfrey's Cordial N.F. 4<https:\/\/americanhistory.si.edu\/collections\/object\/nmah_1255533>."},{"key":"e_1_2_11_6_1","unstructured":"DEA Museum.Mrs. Winslow's Soothing Syrup<https:\/\/museum.dea.gov\/museum\u2010collection\/collection\u2010spotlight\/artifact\/soothing\u2010syrup>."},{"key":"e_1_2_11_7_1","unstructured":"Us Food and Drug Administration.Sulfanilamide Diaster<https:\/\/www.fda.gov\/files\/about%20fda\/published\/The\u2010Sulfanilamide\u2010Disaster.pdf>."},{"key":"e_1_2_11_8_1","unstructured":"US Food and Drug Administration.Promoting Safe and Effective Drugs for 100\u2009Years<https:\/\/www.fda.gov\/files\/Promoting\u2010Safe\u2010and\u2010Effective\u2010Drugs\u2010for\u2010100\u2010Years\u2010%28download%29.pdf>."},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-073604"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70148"},{"key":"e_1_2_11_11_1","unstructured":"US Food and Drug Administration.E11A Pediatric Extrapolation; Guidance for Industry<https:\/\/www.fda.gov\/media\/161190\/download>."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70393"},{"key":"e_1_2_11_13_1","unstructured":"US Food and Drug Administration.S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals<https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/s11\u2010nonclinical\u2010safety\u2010testing\u2010support\u2010development\u2010pediatric\u2010pharmaceuticals>."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1091581818824313"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.70030"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2016.03.001"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2022.107205"},{"key":"e_1_2_11_18_1","unstructured":"US Food and Drug Administration.CDER\/Office of New Drugs Streamlined Nonclinical Studies and Acceptable New Approach Methodologies (NAMs)<https:\/\/www.fda.gov\/about\u2010fda\/center\u2010drug\u2010evaluation\u2010and\u2010research\u2010cder\/cderoffice\u2010new\u2010drugs\u2010streamlined\u2010nonclinical\u2010studies\u2010and\u2010acceptable\u2010new\u2010approach\u2010methodologies\u2010nams>."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105345"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2024.1402630"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfae037"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2022.113429"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1039\/D0LC00417K"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.55730\/1300-0152.2711"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1752-153X-4-S1-S4"},{"key":"e_1_2_11_26_1","article-title":"Prediction of reproductive and developmental toxicity using an attention and gate augmented graph convolutional network","volume":"15","author":"Lee S.H.","year":"2025","journal-title":"Nat Sci Rep"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2025.117435"},{"key":"e_1_2_11_28_1","volume-title":"Machine Learning and Artificial Intelligence in Toxicology and Environmental Health","author":"Jia Q.","year":"2025"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408444.2022.2111252"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-023-03550-z"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/10915818251384270"},{"key":"e_1_2_11_32_1","unstructured":"US Food and Drug Administration.S5(R3) Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals(2021) <https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/s5r3\u2010detection\u2010reproductive\u2010and\u2010developmental\u2010toxicity\u2010human\u2010pharmaceuticals>."},{"key":"e_1_2_11_33_1","unstructured":"US Food and Drug Administration.Considerations for Long\u2010Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development Guidance for Industry(2024) <https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/considerations\u2010long\u2010term\u2010clinical\u2010neurodevelopmental\u2010safety\u2010studies\u2010neonatal\u2010product\u2010development>."},{"key":"e_1_2_11_34_1","first-page":"84","article-title":"Neurodevelopmental outcome at 20 months corrected age in extremely preterm infants after exposure to dexamethasone and hydrocortisone in the NICU","volume":"30","author":"David J.","year":"2025","journal-title":"J Pediatr Pharmacol Ther"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08244-9"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-1-1"},{"key":"e_1_2_11_37_1","unstructured":"US Food and Drug Administration.Pediatric Oncology<https:\/\/www.fda.gov\/about\u2010fda\/oncology\u2010center\u2010excellence\/pediatric\u2010oncology>."},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40064-9"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2024.108686"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2013.02.020"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134315"},{"key":"e_1_2_11_42_1","first-page":"224","article-title":"Opportunities and challenges for human microphysiological systems in drug development","volume":"42","author":"Rahman S.M.","year":"2025","journal-title":"ALTEX"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(02)00846-5"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00942-3"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3845"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2017.02.020"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3845-c1"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2021.107098"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2025.105795"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph13050095"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2024.2366302"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00329-2"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.09.003"},{"key":"e_1_2_11_54_1","unstructured":"Alithea Genomics.Omics in Short\u2010Term Toxicology Studies: Are We Ready to Replace Traditional Approaches?<https:\/\/alitheagenomics.com\/omics\u2010in\u2010short\u2010term\u2010toxicology\u2010studies\u2010are\u2010we\u2010ready\u2010to\u2010replace\u2010traditional\u2010approaches\/>."},{"key":"e_1_2_11_55_1","unstructured":"Tatonetti N.Developing a panel of secondary targets for pediatric developmental safetyIn: Pediatric Developmental Safety Assessment and New Approach Methodologies. <https:\/\/trianglecersi.org\/news\/pediatric\u2010developmental\u2010safety\u2010assessment\u2010and\u2010new\u2010approach\u2010methodologies\u2010workshop\u20102>."},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.129205"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2016.10.024"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/vetsci12080777"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-35214-7.00102-5"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-6997(24)01458-3"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1080285"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.06719.x"},{"key":"e_1_2_11_63_1","first-page":"2067","article-title":"Early expression of all the components of the renin\u2010angiotensin\u2010system in human development","volume":"149","author":"Schutz S.","year":"1996","journal-title":"Am J Pathol"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12565-016-0372-8"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2019.07.006"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhlto.2023.100016"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15553"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27117"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.3390\/biology12050755"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2025.5577"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2004.00525.x"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2005.11.001"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.196352"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.05.045"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/658310"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-207450"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5412138"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.14734\/PN.2021.32.1.48"},{"key":"e_1_2_11_79_1","first-page":"298","article-title":"FDA boxed warnings: how to prescribe drugs safely","volume":"81","author":"O'Connor N.R.","year":"2010","journal-title":"Am Fam Physician"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090872"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063488"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2017.03.002"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3542-17.2018"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2023.102415"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.11941"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(00)00274-0"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15999.x"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2004000800017"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.590787"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2024.111198"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V391575"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006822911586"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00004"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.23.2305"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M104068200"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2017.32"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01213377"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2015.06.048"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9926(199901)59:1<51::AID-TERA10>3.0.CO;2-I"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003896"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1006\/phrs.2000.0758"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1086\/302895"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00335-001-3038-2"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.17.9508"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1242\/dev.041079"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1159\/000531452"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-024-03930-z"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1741-4520.2011.00351.x"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M106117200"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1422865"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2015.08.007"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-024-11022-4"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02270-3"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.727075"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2022.18"},{"key":"e_1_2_11_116_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222679"},{"key":"e_1_2_11_117_1","unstructured":"American College of Rheumatology.Study Finds TNF Blockers Are Not Associated with Poor Pregnancy Outcomes<https:\/\/rheumatology.org\/press\u2010releases\/study\u2010finds\u2010tnf\u2010blockers\u2010are\u2010not\u2010associated\u2010with\u2010poor\u2010pregnancy\u2010outcomes>."},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2264-z"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/852378"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.535195"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25973"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000539"},{"key":"e_1_2_11_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2009.02.003"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.10.2487"},{"key":"e_1_2_11_125_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.653792"},{"key":"e_1_2_11_126_1","unstructured":"US Food & Drug Administration Pediatric Molecular Target Lists (FDA PMTL)<https:\/\/moleculartargets.ccdi.cancer.gov\/fda\u2010pmtl>."},{"key":"e_1_2_11_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2759"},{"key":"e_1_2_11_128_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041656"},{"key":"e_1_2_11_129_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30745"},{"key":"e_1_2_11_130_1","unstructured":"US Food and Drug Administration.Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans: Guidance for Industry(2020) <https:\/\/www.fda.gov\/media\/86340\/download>."},{"key":"e_1_2_11_131_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfad007"},{"key":"e_1_2_11_132_1","unstructured":"ReproTracker: Animal\u2010free developmental toxicity predictions<https:\/\/toxys.com\/reprotracker\/>."},{"key":"e_1_2_11_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2023.153684"},{"key":"e_1_2_11_134_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2990"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70465","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70465","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:23:50Z","timestamp":1792207430000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":134,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1002\/cpt.70465"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70465","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"2026-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}